Antidepressant Incomplete Response Depression

AstraZeneca364 enrolled

Overview

Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 3 assessment will be carried out . The 1st one will be on baseline, the 2sd one after a significant change in pharmacological treatment and 3rd one after a second significant change in pharmacological treatment. If there isn´t any significant change in therapeutic plan a control assessment will be carry out in week 10th and 24th. A significant treatment change is defined as a change in SSRI/SNRI, to add another SSRI/SNRI or a augmentation treatment added to SSRI/SNRI. The primary objective is to describe therapeutical strategies (antidepressant change, association with another antidepressant or association with another treatment) in the management of patients with MDD with incomplete response or intolerance to an antidepressant after a first or a second failure; and when the psychiatrist decide a change of strategy. Secondary objectives include: 1 - To describe the clinic profile of depressive patients with incomplete response or intolerance to an antidepressant after a first or a second failure; 2- To describe the profile of patients based on therapeutic strategies used and number of therapeutic strategies; 4- Evaluate the use of health resource due to lack of fast onset of action, and social cost (productivity, care givers…); 5 - To associate clinical variable with therapeutic action by psychiatrist.

Study Type

OBSERVATIONAL

Enrollment

364

Conditions

Major Depressive Disorder

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of written inform consent * Diagnosed of Major Depressive Disorder based on DSM-IV-TR * Outpatient who has a change in pharmacological therapeutic plan after an incomplete response or intolerance to a treatment with an adequate dosage of an antidepressant (SSRI/NSRI) 5 * Able to understand and to comply with requirements of the study Exclusion Criteria: * Mental retardation * To have been recruited in a clinical trial in the last 4 weeks or to have planned the inclusion in a clinical trial during the follow-up of this study * MDD secondary to substance abuse or somatic illness * Actual depressive episode with \<4 weeks or \>12 months of length * Current treatment with \>1 SSRI/SRNI or previous treatment with \>1 SSRI/SRNI, augmentation treatment with SSRI/SRNI, intravenous antidepressant treatment, TMS, ECT or MAO

Locations (48)

Research Site

Albacete, Albacete, Spain

Research Site

Alcoy, Alicante, Spain

Research Site

Benidorm, Alicante, Spain

Research Site

Villajoyosa, Alicante, Spain

Research Site

Almería, Almeria, Spain

Research Site

Mérida, Badajoz, Spain

Outcomes

Primary Outcomes

Profile of use of 3 group of strategies: 1 - Change to another antidepressive agent (Quetiapine, Lamotrigine, antidepressant…) 2- Association with another antidepressant 3- Association with any other treatment (antipsychotics, lithium…)

Time frame: Baseline, after a significant change in treatment (or control visit after 10th week) and after a 2sd significant change in treatment (or control visit after 24th week).

Secondary Outcomes

Clinical assessment

Time frame: Baseline, after a significant change in treatment (or control visit after 10th week) and after a 2sd significant change in treatment (or control visit after 24th week).

Visits to nurse, psychiatrics: Hospitalization, social support: Productivity assessment

Time frame: Baseline, after a significant change in treatment (or control visit after 10th week) and after a 2sd significant change in treatment (or control visit after 24th week).